Table 1.
Baseline characteristics (n = 94).
| Age | 18–87 y | |
| Sex | Male | Female |
| n (%) | 59 (63%) | 35 (37%) |
| Atopic dermatitis (AD); n (%) | ||
| AD Intrinsic (IgE levels < 150 klU/L) | 11 (11.7%) | |
| AD Extrinsic (IgE levels > 150 klU/L) | 84 (89.4%) | |
| Scores at Baseline | ||
| Investigator Initiated Scores | ||
| IGA a (0–4) | 3.9 ± 0.7 | |
| EASI a (0–72) | 26.5 ± 12.5 | |
| SCORAD a (0–103) | 69.2 ± 11.6 | |
| BSA a (0–100%) | 60.2 ± 19 | |
| Patient-Oriented Scores | ||
| DLQI a (0–30) | 17.3 ± 6.5 | |
| Itch a (0–10) | 7.6 ± 1.7 | |
| Sleep a (0–10) | 7.2 ± 3 | |
| Pain a (0–10) | 6.2 ± 2 | |
| Biomarkers at Baseline | Value (first quartile, third quartile); sample size (n) | |
| Total IgE b klU/L | 3715 (557.5, 5000); n = 66 | |
| ECP b μg/L | 34.4 (24.15, 61,825); n = 30 | |
| LDH b U/L | 245.5 (205, 303.75); n = 64 | |
| Allergic Asthma; n (%) | 26 (27.6%) | |
| Asthma Control Test (ACT) a (0–25) | 18.4 ± 4.9 | |
| Previous Treatments; n (%) | ||
| Topical Treatments (Calcineurin Inhibitors, Corticosteroids) | 94 (100%) | |
| Systemic Treatments | 94 (100%) | |
| Phototherapy (NB UVB/PUVA) | 61 (64.9%) | |
| Cyclosporine A | 34 (36.2%) | |
| Methothrexate | 15 (15.9%) | |
| Azathrioprine | 8 (8.5%) | |
| Other (IVIG c, Omalizumab, Rituximab) | 26 (27.6%) | |
a Mean scores at W0 ± standard deviation; b Median score at baseline (first quartile, third quartile); c intravenous immunoglobulin. IGA: Investigator Global Assessment; EASI: Eczema Area and Severity Index; SCORAD: Scoring Atopic Dermatitis; BSA: Body Surface Area; DLQI: Dermatology Life Quality Index; NB-UVB: narrowband ultraviolet B phototherapy; PUVA: psoralen and ultraviolet A (UVA) therapy; IVIG: intravenous immunoglobulin.